US Researchers Published Scientific Findings that
Post# of 297
Posted On: 12/01/2014 7:27:00 AM
US Researchers Published Scientific Findings that are a Potential Breakthrough for Prevention of Neuropathic Pain by CF101
| 6:00 AM |
[PR Newswire] - According to the research, the latter binds with high affinity to the A3 adenosine receptor and via specific mechanistic pathways significantly reduces neuropathic pain in animal models. Can-Fite CEO Dr. Pnina Fishman commented on these findings, stating, "It is very interesting that our drugs have additional well-defined clinical application in the field of neuropathic pain which is an unmet need. While Can-Fite holds an exclusive worldwide license from NIH for clinical development of IB-MECA and Cl-IB-MECA, these compounds may be used for basic research purposes in the lab. Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (CFBI.TA) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer and inflammatory diseases.
http://us.rd.yahoo.com/finance/news/rss/story...00713.html
~ This Week's OTC News In Review! ~
Covering the entire market and teaching traders! Visit here to learn technicals and fundamentals >>
http://www.stockgoodies.com/lessons.html
~ http://www.fallenheroesfund.org/ ~
St. Jude 2014 Drive has started >> http://tinyurl.com/St-Jude-2014
| 6:00 AM |
[PR Newswire] - According to the research, the latter binds with high affinity to the A3 adenosine receptor and via specific mechanistic pathways significantly reduces neuropathic pain in animal models. Can-Fite CEO Dr. Pnina Fishman commented on these findings, stating, "It is very interesting that our drugs have additional well-defined clinical application in the field of neuropathic pain which is an unmet need. While Can-Fite holds an exclusive worldwide license from NIH for clinical development of IB-MECA and Cl-IB-MECA, these compounds may be used for basic research purposes in the lab. Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (CFBI.TA) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer and inflammatory diseases.
http://us.rd.yahoo.com/finance/news/rss/story...00713.html
~ This Week's OTC News In Review! ~
Covering the entire market and teaching traders! Visit here to learn technicals and fundamentals >>
http://www.stockgoodies.com/lessons.html
~ http://www.fallenheroesfund.org/ ~
St. Jude 2014 Drive has started >> http://tinyurl.com/St-Jude-2014
(0)
(0)Scroll down for more posts ▼